FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>van Dijk Marcus Antonius</u>					2. Issuer Name and Ticker or Trading Symbol MiNK Therapeutics, Inc. [ INKT ]								eck all applic Directo	or		10% Ow	ner		
(Last)	`	irst) E, SUITE 500	(Middle)			Date o		Transa	action (Mon	th/Da	ay/Year)		helow)	Officer (give title below)  Chief Scier		Other (s below) Officer	pecify		
(Street) NEW YO		tate)	10010 (Zip)		-									Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				ay/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 5) 8 4. Securities Acquire Disposed Of (D) (Instr. 5)			Securitie Beneficia Owned F	. Amount of ecurities eneficially wned Following		Direct Indirect I	7. Nature of Indirect Beneficial Ownership					
								Code V	,	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Transact					6. Date Exercis Expiration Date (Month/Day/Yea		of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
Cod					Code	v	(A)		Date Exercisable		piration te	Title	Amount or Number of Shares	mber					
Stock Option	\$2.32	01/09/2023			Α		15,000		(1)	01/	/09/2033	Common Stock	15,000	\$0.00	15,000	0	D		

## Explanation of Responses:

1. Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

## Remarks:

By: /s/ Christine Klaskin, Attorney-in-Fact for Marcus

01/11/2023

Antonius van Dijk \*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.